Earth exoplanets orbiting M-dwarf stars, identifying specific candidates that may have retained detectable atmospheres.
The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also granted traditional approval for the treatment of relapsed or refractory FL ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
Ark., ran for reelection in 2020, his potential Democratic opponent withdrew nearly a year before Election Day, giving the ...
New observations of the red giant star R Doradus suggest starlight alone cannot drive stellar winds that spread key elements through the galaxy.
KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL. Researchers determined zanubrutinib plus obinutuzumab demonstrated sustained ...
The study also relied on the historical context provided by the University of Hawaiʻi at Mānoa Hawai‘i Ocean Time-series ...
Findings from the phase 1/2 BRUIN study (NCT03740529) show that pirtobrutinib (Jaypirca), a Bruton tyrosine kinase inhibitor (BTKi), monotherapy offers promising clinical efficacy and a favorable ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback